PharmacoEconomics

The Future Costs, Risks and Rewards of Drug Development: The Economics of Pharmacogenomics
pp. 355-363(9)
Authors: Cook, Joseph; Hunter, Graeme; Vernon, John A.

The Cost and Impact of Health Conditions on Presenteeism to Employers: A Review of the Literature
pp. 365-378(14)
Authors: Schultz, Alyssa B.; Chen, Chin-Yu; Edington, Dee W.

Costing Infectious Disease Outbreaks for Economic Evaluation: A Review for Hepatitis A
pp. 379-389(11)
Authors: Luyten, Jeroen; Beutels, Philippe

The Cost of Dementia in Europe: A Review of the Evidence, and Methodological Considerations
pp. 391-403(13)
Authors: Jönsson, Linus; Wimo, Anders

Utility Assessment in Patients with Mental Disorders: Validity and Discriminative Ability of the Time Trade-Off Method
pp. 405-419(15)
Authors: König, Hans-Helmut; Günther, Oliver H.; Angermeyer, Matthias C.; Roick, Christiane

Outcomes Associated with Initial versus Later Vancomycin Use in Patients with Complicated Skin and Skin-Structure Infections
pp. 421-430(10)
Authors: Itani, Kamal M.F.; Akhras, Kasem S.; Stellhorn, Robert; Quintana, Alvaro; Budd, David; Merchant, Sanjay

Pharmaceutical Risk-Sharing Agreements
pp. 431-432(2)
Author: Gandjour, Afschin

Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium
pp. 433-433(1)
Authors: Cleemput, Irina; Thiry, Nancy

The Author's Reply
pp. 433-434(2)

Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs
pp. 435-438(4)
Authors: Godman, Brian; Schwabe, Ulrich; Selke, Gisbert; Wettermark, Björn